Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

CorMedix (CRMD) Shares Outstanding (Diluted Average) (2021 - 2025)

CorMedix's Shares Outstanding (Diluted Average) history spans 7 years, with the latest figure at $71.9 million for Q2 2025.

  • For Q2 2025, Shares Outstanding (Diluted Average) rose 24.94% year-over-year to $71.9 million; the TTM value through Jun 2025 reached $71.9 million, up 24.94%, while the annual FY2024 figure was $58.9 million, N/A changed from the prior year.
  • Shares Outstanding (Diluted Average) for Q2 2025 was $71.9 million at CorMedix, up from $69.0 million in the prior quarter.
  • Across five years, Shares Outstanding (Diluted Average) topped out at $71.9 million in Q2 2025 and bottomed at $37.2 million in Q2 2021.
  • The 5-year median for Shares Outstanding (Diluted Average) is $44.4 million (2023), against an average of $49.4 million.
  • The largest annual shift saw Shares Outstanding (Diluted Average) surged 37.32% in 2023 before it increased 2.53% in 2024.
  • A 5-year view of Shares Outstanding (Diluted Average) shows it stood at $37.7 million in 2021, then grew by 6.92% to $40.3 million in 2022, then skyrocketed by 40.42% to $56.6 million in 2023, then increased by 4.1% to $58.9 million in 2024, then rose by 22.16% to $71.9 million in 2025.
  • Per Business Quant, the three most recent readings for CRMD's Shares Outstanding (Diluted Average) are $71.9 million (Q2 2025), $69.0 million (Q1 2025), and $58.9 million (Q4 2024).